2023
Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutrition
2022
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux C, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity 2022, 30: 2340-2350. PMID: 36268562, DOI: 10.1002/oby.23599.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationManagement of obesityKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planObstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. American Journal Of Kidney Diseases 2022, 80: 783-793. PMID: 36280397, DOI: 10.1053/j.ajkd.2022.06.007.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsManagement of obesityLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action plan
2021
Treating the Chronic Disease of Obesity
Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Medical Clinics Of North America 2021, 105: 983-1016. PMID: 34688422, DOI: 10.1016/j.mcna.2021.06.005.Peer-Reviewed Original ResearchConceptsChronic diseasesIntensive lifestyle interventionAvailable therapeutic modalitiesPrimary care providersTreatable chronic diseaseCare of patientsAntiobesity pharmacotherapiesBariatric surgeryLifestyle interventionSafe therapyComprehensive careTherapeutic modalitiesCare providersTreatment approachesObesityPatientsDiseaseCarePharmacotherapySurgeryTherapyDiagnosis
2019
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, Pratt JSA, Bolling C, Michalsky MP, Cook S, Lenders CM, Apovian CM. Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. Obesity 2019, 27: 190-204. PMID: 30677262, PMCID: PMC6449849, DOI: 10.1002/oby.22385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIntensive lifestyle interventionObesity pharmacotherapyLifestyle interventionSevere obesityPrediabetes/type 2 diabetesObesity-related comorbid diseasesNonalcoholic fatty liver diseasePediatric primary care providersIntensive lifestyle modificationFatty liver diseaseMore effective treatment strategiesObstructive sleep apneaEffective treatment optionPrimary care providersType 2 diabetesEffective treatment strategiesLifestyle modificationPharmacotherapy optionsBariatric surgeryComorbid diseasesLiver diseaseSleep apneaTreatment algorithmExcess adiposityInformed consent regulations